Company news

Almirall SA news in 2026

Almirall SA's news releases, calls and decks from 2026, newest first.

View company

EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab

October 1, 2026

Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026

September 30, 2026

Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology

August 10, 2026

Almirall H1 2026 Results

July 24, 2026

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

July 20, 2026

Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business

May 11, 2026

Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology

April 13, 2026

Almirall enters collaboration with Huaota for the development of a novel monoclonal antibody in medical dermatology

March 30, 2026

Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis

March 27, 2026

AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne

March 26, 2026

Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology

March 23, 2026

Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis

March 16, 2026

Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships

March 12, 2026

etherna's intratumoral mRNA/LNP platform advances to clinical testing in nonmelanoma skin cancer led by Almirall

February 24, 2026

Almirall’s 2025 Results

February 23, 2026

EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall

February 9, 2026

Almirall Announces the Approval of Seysara® in China for the Treatment of Moderate-to-Severe Acne

January 29, 2026

Almirall Announces "LumiNE", a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema

January 15, 2026

Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference

January 14, 2026

Calls in 2026

Decks in 2026